



10/66 111


AUG 19 2005

Amendments to the Claims:

-2-

PC25382A

1. (Original Currently Amended) A compound of formula (I),



wherein

m is 1, 2 or 3;

R¹ is methyl, chloro, bromo or fluoro;

R² is -Q¹-Q²-Q³-Q⁴ or (C₁-C₆)alkyl,

- said (C₁-C₆)alkyl is substituted with one to three OR⁴, COOR⁴, NR⁴R⁵, NRC(=O)R⁴, C(=O)NR⁴R⁵ or SO₂NR⁴R⁵;
- R⁴ is (C₁-C₆)alkyl substituted with one to three F, CN, S(=O)R⁶, SO₃H, SO₂R⁶, SR⁷, C(=O)-NH-SO₂-CH₃, C(=O)R⁷, NR'C(=O)R⁷, NR'SO₂R⁶, C(=O)NR⁷R⁸, O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸;
- R⁵ is H or (C₁-C₆)alkyl optionally substituted with one to three F, CN, S(=O)R⁶, SO₃H, SO₂R⁶, SR⁷, C(=O)-NH-SO₂-CH₃, C(=O)R⁷, NR'C(=O)R⁷, NR'SO₂R⁶, C(=O)NR⁷R⁸, O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; or
- said (C₁-C₆)alkyl is
 - 1) substituted with one to three OC(=O)R^{4a}, SR^{4a}, S(=O)R³, C(=NR⁹)R^{4a}, C(=NR⁹)-NR^{4a}R^{5a}, NR-C(=NR⁹)-NR^{4a}R^{5a}, NRCOOR^{4a}, NR-C(=O)-NR^{4a}R^{5a}, NR-SO₂-NR^{4a}R^{5a}, NR-C(=NR⁹)-R^{4a} or NR-SO₂-R³; and
 - 2) optionally substituted with one or two OR^{4a}, COOR^{4a}, C(=O)-R^{4a}, NR^{4a}R^{5a}, NRC(=O)R^{4a}, C(=O)NR^{4a}R^{5a} or SO₂NR^{4a}R^{5a};
- R⁹ is H, CN, OH, OCH₃, SO₂CH₃, SO₂NH₂ or (C₁-C₆)alkyl; and
- R³ is (C₁-C₆)alkyl optionally substituted with one to three F, CN, S(=O)R⁶, SO₃H, SO₂R⁶, C(=O)-NH-SO₂-CH₃, OR⁷, SR⁷, COOR⁷, C(=O)R⁷, O-C(=O)NR⁷R⁸, NR⁷R⁸, NR'C(=O)R⁷, NR'SO₂R⁶, C(=O)NR⁷R⁸ or SO₂NR⁷R⁸;

- R^{4a} and R^{5a} are the same or different and are H or $(C_1\text{-}C_6)\text{alkyl}$ optionally substituted with one to three F, CN, $S(=O)R^6$, SO_3H , SO_2R^6 , $C(=O)\text{-NH-}SO_2$ - CH_3 , OR^7 , SR^7 , $COOR^7$, $C(=O)R^7$, $O\text{-}C(=O)NR^7R^8$, NR^7R^8 , $NR^7C(=O)R^7$, $NR^7SO_2R^6$, $C(=O)NR^7R^8$ or $SO_2NR^7R^8$;
- Q^1 is a single bond or $(C_1\text{-}C_6)\text{alkylene}$;
- Q^2 is a saturated 4- to 6-membered heterocyclyl comprising one or two O or N;
- Q^3 is $(C_1\text{-}C_6)\text{alkylene}$;
- Q^4 is a 4 to 8-membered, aromatic or non aromatic, heterocyclyl comprising 1 to 4 -O-, -S-, - $S(=O)$ -, - SO_2 - or -N-, said heterocyclyl being optionally substituted with one to three -OR, -NRR', -CN or $-(C_1\text{-}C_6)\text{alkyl}$;
- R is H or $(C_1\text{-}C_6)\text{alkyl}$;
- R^6 is $(C_1\text{-}C_6)\text{alkyl}$ optionally substituted with one or two -OR';
- R^7 and R^8 are the same or different and are H or $(C_1\text{-}C_6)\text{alkyl}$ optionally substituted with one or two -OR';
- R^9 is H, -CN, -OH, -OCH₃, -SO₂CH₃, -SO₂NH₂ or $-(C_1\text{-}C_6)\text{alkyl}$;
- R' is H or $(C_1\text{-}C_6)\text{alkyl}$; and
- R'' is H or $(C_1\text{-}C_6)\text{alkyl}$;
- provided that
 - 1) the atom of Q^2 bound to Q^1 is a carbon atom; and
 - 2) the atom of Q^4 bound to Q^3 is a carbon atom;
 or a racemic form, isomer, pharmaceutically acceptable salts, hydrates, solvates and polymorphs derivative thereof.

2. (Original) A compound of claim 1 wherein R^2 is $(C_1\text{-}C_6)\text{alkyl}$ substituted with -OR⁴, -COOR⁴, -NR⁴R⁵, NRC(=O)R⁴, -C(=O)NR⁴R⁵ or -SO₂NR⁴R⁵; R⁴ is $(C_1\text{-}C_6)\text{alkyl}$ substituted with one to three -S(=O)R⁶, -SO₂R⁶, -NR'C(=O)R⁷, -NR'SO₂R⁶, -C(=O)NR⁷R⁸, -O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; R⁵ is H or $(C_1\text{-}C_6)\text{alkyl}$ optionally substituted with one to three -S(=O)R⁶, -SO₂R⁶, -NR'C(=O)R⁷, -NR'SO₂R⁶, -C(=O)NR⁷R⁸, -O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; R⁶ is $(C_1\text{-}C_6)\text{alkyl}$; and R', R⁷ and R⁸ are the same or different and are H or $(C_1\text{-}C_6)\text{alkyl}$.

3. (Original) A compound of claim 1 wherein R² is (C₁-C₆)alkyl substituted with -NR⁴R⁵ or -C(=O)NR⁴R⁵; R⁴ is (C₁-C₆)alkyl substituted with -S(=O)CH₃, -NHC(=O)CH₃ or -C(=O)NR⁷R⁸; R⁵ is H or methyl; and R⁷ and R⁸ are the same or different and are H or methyl.

4. (Original) A compound of claim 1 wherein R² is (C₁-C₆)alkyl substituted with one to three -OC(=O)R^{4a}, -SR^{4a}, -S(=O)R³, -NRCOOR^{4a}, -NR-C(=O)-NR^{4a}R^{5a}, -NR-SO₂-NR^{4a}R^{5a} or -NR-SO₂-R³; and said (C₁-C₆)alkyl is optionally substituted with -OH or -OCH₃; R is H or CH₃; R³ is (C₁-C₆)alkyl optionally substituted with one to three -F, -CN, -S(=O)R⁶, -SO₃H, -SO₂R⁶, -C(=O)-NH-SO₂-CH₃, -OR⁷, -SR⁷, -COOR⁷, -C(=O)R⁷, -O-C(=O)NR⁷R⁸, -NR'C(=O)R⁷, -NR'SO₂R⁶, -C(=O)NR⁷R⁸ or -SO₂NR⁷R⁸; R^{4a} and R^{5a} are the same or different and are H, (C₁-C₆)alkyl optionally substituted with one to three -F, -CN, -S(=O)R⁶, -SO₃H, -SO₂R⁶, -C(=O)-NH-SO₂-CH₃, -OR⁷, -SR⁷, -COOR⁷, -C(=O)R⁷, -O-C(=O)NR⁷R⁸, -NR'C(=O)R⁷, -NR'SO₂R⁶, -C(=O)NR⁷R⁸ or -SO₂NR⁷R⁸; R⁶ is (C₁-C₆)alkyl; and R⁷, R⁷ and R⁸ are the same or different and are H or (C₁-C₆)alkyl.

5. (Original) A compound of claim 1 wherein R² is (C₁-C₆)alkyl substituted with -S(=O)R³; R³ is (C₁-C₆)alkyl optionally substituted with one to three -S(=O)R⁶, -SO₂R⁶, -NR⁷R⁸, -OR⁷, -NR'C(=O)R⁷, -NR'SO₂R⁷; -C(=O)NR⁷R⁸; or -O-C(=O)NR⁷R⁸; R⁶ is (C₁-C₆)alkyl; and R⁷, R⁷ and R⁸ are the same or different and are H or (C₁-C₆)alkyl.

6. (Original) A compound of claim 1 wherein R² is (C₁-C₆)alkyl substituted with -S(=O)R³; and R³ is (C₁-C₆)alkyl, preferably methyl.

7. (Original) A compound of claim 1 wherein R² is Q¹-Q²-Q³-Q⁴; Q² is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom; Q³ is a linear (C₁-C₄)alkylene group; Q⁴ is a 5- or 6-membered aromatic heterocycle comprising one to four nitrogen atoms, said heterocycle being optionally substituted with methyl.

8. (Original) A compound of claim 1 wherein R² is Q¹-Q²-Q³-Q⁴; Q¹ is a single bond; Q² is a saturated 4 to 6-membered heterocycle comprising a nitrogen atom; Q³ is -CH₂-; and Q⁴ is a 5-membered, aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl.

9. (Original) A compound of claim 8 wherein R¹ is -Cl or -F.

10. (Original) A compound of claim 8 wherein m is 2.

11. (OriginalCurrently Amended) A compound according to claim 8 and selected from 5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; 8'-chloro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; 5'-(2-{{2-(acetylamino)ethyl}amino}ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; 8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; 8'-fluoro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; or 8'-fluoro-5'-(2-{{1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl}oxy}1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one.

12. (OriginalCanceled) A method of treating a disease for which PDE7 inhibition therapy is indicated in a mammal comprising administering to said mammal in need thereof a compound of claim 1.

13. (OriginalCurrently Amended) A method of claim 12 wherein said treating a disease is selected from T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, leukemia, acquired immune deficiency syndrome (AIDS),

allergy, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, pancreatitis, dermatoses, psoriasis, atopic dermatitis, glomerulonephritis, conjunctivitis, autoimmune diabete, graft rejection, epilepsy, muscular atrophy and systemic lupus erythematosus in a mammal comprising administering to said mammal in need thereof, a compound of claim 1.

14. (Original) A method of claim 13 wherein said disease is asthma, allergy or atopic dermatitis.

15. (Original) A method of claim 13 wherein said disease is osteoporosis.

16. (Original) A method of claim 13 wherein said disease is cancer.

17. (Original) A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.